Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Silence Therapeutics has promoted Anthony David Sedgwick as chief executive officer (CEO) from the post of chief business officer following the resignation of Thomas Christély as a director of the company.
Subscribe to our email newsletter
Tony Sedgwick has joined the company in September 2011 and has extensive experience from European life science companies including more than fifteen years at Roche.
Prior to joining Silence, Tony was CEO of Novacta and chairman of the Norwegian biotech company Plastid.
He also worked as CEO for Daniolabs and Cambridge Biotechnology.
Tony Sedgwick holds 1,108,108 shares (0.19%) of the issued share capital in the company.
Silence Therapeutics is a biotechnology company focused on the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.